

SCOLR Pharma, Inc.  
Form 8-K  
March 26, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant To Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report: March 20, 2012**

**(Date of earliest event reported)**

**SCOLR Pharma, Inc.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: SCOLR Pharma, Inc. - Form 8-K

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)  
**13400 NE 20<sup>th</sup> Street, Suite 44**

(I.R.S. Employer  
Identification No.)

**Bellevue, WA 98005**

(Address of principal executive offices and zip code)

**(425) 368-1050**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**SCOLR PHARMA, INC.**

**FORM 8-K**

**Item 1.01 Entry into a Material Definitive Agreement.**

On March 20, 2012, SCOLR Pharma, Inc. (the Company) executed two Demand Promissory Notes, one in favor of Michael N. Taglich, a member of the Company's Board of Directors, and the other in favor of Robert Taglich, his brother (each a Note, and together, the Notes). Each note has an original principal amount of \$100,000 and bears interest at a rate of eight percent (8%) per annum. The Notes are unsecured and are payable on demand. The applicable interest rate on the Notes increases to twelve percent (12%) upon the occurrence and during the continuance of an event of default, including the Company's failure to pay the notes when due, subject to an applicable cure period.

Copies of the Notes are attached as Exhibit 10.1 and 10.2 to this current report and are incorporated herein by reference. The foregoing description of the Notes does not purport to be complete and is qualified in its entirety by reference to such exhibits.

**Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.**

The disclosure contained under Item 1.01 above is incorporated into this item by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

| <b>Exhibit No.</b> | <b>Description</b>   |
|--------------------|--|
| 10.1               | Demand Promissory Note, dated March 20, 2011, issued by SCOLR Pharma, Inc. in favor of Michael N. Taglich. |
| 10.2               | Demand Promissory Note, dated March 20, 2011, issued by SCOLR Pharma, Inc. in favor of Robert Taglich      |

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCOLR Pharma, Inc.  
(Registrant)

March 26, 2012  
(Date)

By: /s/ RICHARD M. LEVY  
**Richard M. Levy**  
**Executive Vice President & Chief Financial Officer**